Long-term control of macroprolactinomas.

摘要: Hyperprolactinemia is the most prevalent hypothalamic–pituitary dysfunction, with prolactinomas being its main cause. Microprolactinomas (diameter < 10 mm) represent approximately 60% of prolactin-secreting adenomas, and are far more common in women than men, whereas macroadenomas have roughly same prevalence both genders. The treatment patients harboring macroprolactinomas highly gratifying, 80% them adequately controlled by dopamine-agonist (DA) drugs: cabergoline efficacious to date. Emerging evidence points remission disease after long-term DA therapy a significant number patients. remaining cases, mainly those enclosed tumors, may be treated successfully pituitary surgery. Radiotherapy reserved for cases dopaminergic drug resistance not surgically cured. development new therapeutic approaches turn control subset refractory surgery into reality.